Abstract The Forkhead Box Protein 3 is highly expressed not only in regulatory T cells, but also in tumor cells, acting as a transcriptional repressor of breast oncogenes including HER2. We investigated the prognostic significance of Foxp3 expression in cancer cells in a large cohort of patients with HER2-overexpressing breast carcinoma treated with neoadjuvant chemotherapy. Foxp3-positive tumor cells were detected by immunohistochemistry in 103 patients with primary invasive HER2-overexpressing breast carcinoma, and treated with neoadjuvant chemotherapy, with or without trastuzumab. Kaplan-Meier analysis and Cox regression model were used to assess relapse-free and overall survival, respectively, and according to the presence or the absence of Foxp3 expression in tumor cells. Breast cancer cells were Foxp3? in 57% of tumors. Foxp3 expression in breast cancer cells was associated with better relapse-free (P = 0.005) and overall survival (P = 0.03). By multivariate analysis, the presence of Foxp3? tumor cells produced an independent prognostic factor for both better relapse-free (P = 0.006) and overall survival (P = 0.03). These findings indicate that the presence of Foxp3? tumor cells represents a new independent prognostic factor of improved outcome in HER2-overexpressing breast carcinoma, which could help identify high-risk patients for additional therapies after neoadjuvant chemotherapy.
Introduction
Forkhead Box Protein 3 (Foxp3) is a transcription factor involved in regulating immune system development [1, 2] , notably in the generation of immunosuppressive regulatory T cells (Treg). These cells play a central role in preventing autoimmunity and pathologies inflicted due to uncontrolled immune responses after infection [3] . Moreover, there is increasing evidence that Treg also play an important role in immune evasion mechanisms promoted by cancers, enabling tumor cells to elude the host antitumor immune response [4] [5] [6] [7] [8] [9] . Initially, Foxp3 expression was thought to be restricted to hematopoietic tissues. However, although data are scant, Foxp3 expression by other tissues has also been observed, including in human tumor cells [10] . Importantly, biological functions of Foxp3 in tumor cells, and its significance, presently remain unclear. Recent data suggest that Foxp3 expression in tumor cells could be a poor prognostic factor in breast cancer [11] , but in contrast with these data, Foxp3 was also recently demonstrated to be a tumor suppressor gene, acting as a transcriptional repressor of SKP2 and HER2, the two breast cancer oncogenes [12, 13] . These two biological studies suggested that HER2-overexpressing breast cancer subtype may be differently driven by Foxp3. This led us to hypothesize that Foxp3 expression may have antitumor functions in HER2-overexpressing molecular subtype of breast cancer, and, therefore, a different prognostic significance.
This study examined the prognostic relevance of tumor cell Foxp3 expression in archival material of a cohort of 103 consecutive patients treated with neoadjuvant chemotherapy for HER2-overexpressing breast cancer.
Importantly, this study reveals that, in this molecular subtype, the presence of Foxp3 expression in tumor cells independently predicts a better survival after neoadjuvant chemotherapy.
Patients and methods

Patients and tissue sampling
Our series included 103 consecutive patients treated with neoadjuvant chemotherapy in our institution (Centre Regional de Lutte Contre le Cancer de Dijon, Dijon, France) between 1976 and 2007 for localized breast carcinoma overexpressing HER2. All the patients underwent neoadjuvant chemotherapy followed by definitive surgery and radiotherapy. This retrospective study was approved by our institutional review board, and all the data were anonymized. Written informed consent was obtained from all the patients. All the patients were diagnosed with invasive breast carcinoma by core needle biopsy, and a sample was collected in association with anonymized clinical data.
Histologic type was defined according to the WHO classification. Histologic grading was carried out using the Nottingham-combined histologic grade (Elston-Ellis modification of Scarff-Bloom-Richardson (SBR) grading system) [14] . The steroid hormone receptor estrogen, and progesterone receptor status was determined using enzymeimmunoassays (Abbott Diagnostics, Abbott Park, Illinois, USA), or by immunohistochemistry (ER, clone SP1, PR clone 1E2, Ventana, Tucson USA). The Herceptest scoring method was used for the determination of HER2 status, considering only a score of 3?, or 2? with FISH amplification, as determinants for HER2 overexpressing tumors (clone 4B5, Ventana, Tucson USA).
Chemotherapy was performed using an anthracyclinebased regimen ( [15] . Breast tissue without residual malignant epithelial invasive tumor, and associated with no microscopic evidence of tumor cell in axillary specimens, was considered as pathological complete response (pCR).
Foxp3 immunohistochemical staining
Foxp3 expression was analyzed immunohistochemically on formalin-fixed, paraffin-embedded tumor sections using Antihuman Foxp3 monoclonal antibody clone ab20034 (Abcam, Cambridge, United Kingdom) at 1/100 dilution, and the iVIEW system (Ventana, Tucson USA). Labeling was detected using the Ventana Benchmark XT automat (Ventana, Tucson USA). The stained arrays were counterstained with hematoxylin and mounted in Aquamount (Dako, Glostrup, Denmark). Positive and negative staining controls were carried out with paraffin tonsil sections using Foxp3 monoclonal antibody and an isotype-matched negative control antibody. The presence or the absence of Foxp3-positive (Foxp3?) tumor cells, and quantification of Foxp3? Treg were evaluated independently by two of the authors (S.L and F.G), both blinded to clinical data. Discrepancies between the 2 observers were reviewed jointly, and a consensus was reached. In order to evaluate the extent of Foxp3? Treg cells infiltration, a grading system for semiquantitative scoring based on the system established by Black [16] , and previously described and validated to assess Treg infiltration [17] was used. Briefly, at least 10 fields were assessed: grade 0 corresponds to the absence of Foxp3? Treg cells, grade 1 corresponds to the presence of 1 to 3 Foxp3? Treg cells in less than three fields, grade 2 corresponds to the presence of 1 to 3 Foxp3? Treg cells in more than three fields, and grade 3 corresponds to the presence of more than 3 Foxp3? Treg cells in more than three fields. Grades 0 and 1 were considered as low infiltration, whereas grades 2 and 3 were considered as strong Treg infiltration.
Statistical analysis
The association between the presence of Foxp3? tumor cells/or Foxp3? Treg cells infiltration and clinicopathological/biological variables was examined using the Chi2 test and Fisher's exact probability test if required. Relapse-free survival (RFS) was defined as the time elapsed from the date of diagnosis to the date of the first event (locoregional recurrence and/or a distant recurrence, whichever came first). Overall survival (OS) was defined as the time from date of diagnosis until death. The KaplanMeier method was used for calculation of survival probabilities and the log-rank test for comparison of survival curves. Cox's proportional hazards regression was used for univariate and multivariate analysis of RFS and OS. All the predictors with P values lower than 0.10 in univariate analysis were used in multivariate analysis, carried out by the backward elimination procedure. Foxp3 and treatment interaction terms were included in the models with significance testing by the likelihood ratio test.
All the analyses were conducted using Medcalc software (Medcalc Software, Mariakerke, Belgium). Two-sided P values less than 0.05 were considered statistically significant.
Results
Patient characteristics
In total, 103 patients were included in this analysis. Patient and tumor characteristics are reported in Table 1 . Half of all the patients presented with stage T3 or T4 tumor and 72% had clinically detectable axillary lymph node involvement at diagnosis. Half the patients presented with high tumor grade (SBR III) and/or negative estrogen receptor. Neoadjuvant chemotherapy was given every 3 weeks for a total of six cycles, and consisted of an anthracycline-based regimen in 48 cases (47%), and trastuzumab ? taxane-based regimen in 55 cases (53%). Classic histological analysis of surgical specimens revealed a pCR in 27 cases (25%) (19/55 (33%) in the group treated by trastuzumab ? taxane and 8/48 (16%) in the group treated by anthracycline-based regimen). Median follow-up period was 40 months (range 7-144).
Foxp3 expression in breast cancer tumor cells
Of the 103 tumor specimens, 59 (57%) were found to express Foxp3 in tumor cells. Foxp3 staining was always localized in the cytoplasm of breast cancer cells (Fig. 1a,  d ), in contrast to the nuclear staining of Treg cells (Fig. 1d,  e) . Table 2 lists the frequency of prognostic clinicopathologic characteristics, according to the presence or the absence of Foxp3 immunostaining. No significant association was found between expression of Foxp3 in tumor cells and prognostic parameters (tumor size, estrogen receptor status, lymph node status, type of chemotherapy, histological response after neoadjuvant chemotherapy), except for tumor grade (P = 0.046). Frequency of Foxp3? tumor cells was not significantly different between patients treated with or without trastuzumab (P = 0.69).
Prognostic significance of Foxp3 expression in breast cancer cells overexpressing HER2
Univariate analysis of clinical and pathological characteristics (Table 3) indicated that neither age [ 50, tumor stage C T3, axillary nodal involvement, high tumor grade, or negative estrogen receptor was associated with an increased risk of relapse (RFS) or death (OS). Only the presence of pathologic complete response on surgical specimen (P = 0.01; HR 0.31 95% CI 0.11-0.88 and P = 0.038; HR 0.53 95% CI 0.15-0.82 respectively), chemotherapy with trastuzumab (P = 0.001; HR 0.32 95% CI 0.15-0.69 and P = 0.002; HR 0.05 95% CI 0.006-0.35 respectively), and the presence of Foxp3? tumor cells (P = 0.007; HR 0.40 95% CI 0.21-0.78 and P = 0.040; HR 0.46 95% CI 0.22-0.95 respectively) were significantly associated with lower risk of relapse (RFS) or death (OS). Presence of Foxp3? tumor cells confers significantly better RFS (log-rank test P = 0.005) and OS (log-rank test P = 0.03) (Fig. 2a, b) . Of note, the probability of 10-year survival was 73% for patients with Foxp3? tumor cells, and only 42% in the Foxp3-tumor cells group. We then performed a subgroup analysis in anthracycline and trastuzumab group. In the anthracycline group, the the presence 2-3) . By univariate analysis, high Foxp3? Treg infiltration was not significantly associated with an increased risk of relapse (RFS) or death (OS), whatever treatment received (e.g., anthracyclines or trastuzumab-based chemotherapy) ( Table 5) .
Discussion
Foxp3 is a member of the forkhead family of transcription factors critically involved in the development and functions of Treg cells, and is, thus far, the most specific marker of this cell subtype [18] . Increased numbers of tumor-infiltrating Treg cells have been demonstrated in various types of cancer [5, 19, 20] , and their presence in elevated numbers among T cells infiltrating tumors is associated with poor prognosis in breast [21] and ovarian cancer [5] . Until recently, Foxp3 expression was thought to occur mainly in Treg cells and some populations of activated T cells. However, recent studies have provided clear evidence that Overall survival probability (%)
Number at risk Merlo et al. [11] recently reported that Foxp3 was expressed in 57% of 183 patients bearing a localized breast cancer; a rate similar to that found in our study. Interestingly, the authors identified tumor cell Foxp3 expression as a new independent factor of poor prognosis for relapse-free and overall survival. However, the potential function of Foxp3 in tumor cells and the mechanism by which Foxp3 expression in breast cancer cells could affect prognosis remain unclear. In apparent contradiction with Merlo's data, Zuo et al. [12, 13] recently reported that Foxp3 acts as a transcriptional repressor for the breast cancer oncogenes SKP2 and HER2, suppressing breast tumor cell growth. Moreover, induction of Foxp3 expression in breast cancer cell lines could induce apoptosis and abrogate tumor growth in murine models [12, 13, 24] . These biological data suggested that the function of Foxp3 in cancer cells may depend on the nature of the breast tumor, especially concerning oncogenic pathways involved in tumor growth. Interestingly, in our series of HER2-overexpressing breast patients, Foxp3 expression in breast cancer cells was associated with better long-term prognosis and constituted an independent prognostic factor for better relapse-free and overall survival.
These contradictory results with Merlo's study are probably explained by differences in the studied populations. First, we limited our study to patients with HER2-overexpressing breast cancer. In Merlo's study, only 15% of the patients harboured HER2-overexpressing carcinomas. Moreover, no prognostic stratification upon breast cancer histological subtypes was performed. Another important difference with our study is that all our patients received neoadjuvant chemotherapy before surgical resection, and then radiotherapy, whereas only a limited number of patients reported by Merlo et al. received postsurgical chemotherapy.
A nuclear localization of Foxp3 is observed in Treg but also in the epithelial cells of mouse [25] and human [13] normal mammary glands. Our study reveals that, in HER2-overexpressing breast cancer cells, Foxp3 staining was only observed in the cytoplasm. These results are in accordance with those from Zuo et al., who demonstrated that Foxp3 could be expressed in the nucleus of normal or tumoral epithelial breast cells. Importantly this nuclear expression seemed to be restricted to HER negative tumors. However, Foxp3 cytoplasmic expression was not tested in this study [13] . In a recent article about Foxp3 expression in prostate cancer cells [26] , the same team of investigators demonstrated that genetic Foxp3 mutation could be detected in cancer cells and restrained its expression in the cytoplasm as in our series of HER overexpressing patients. Nonetheless, the prognostic role of the cytoplasmic expression of Foxp3 was not tested in this study. A cytoplasmic localization of Foxp3 was observed in cancer cells from various human carcinomas [10, 22] , including human breast carcinoma. Cytoplasmic rather than nuclear localization of Foxp3 could result from somatic mutations. Foxp3 molecule contains a winged-helix/forkhead (FKH) domain that includes a putative nuclear localization signal. Mutations of this domain can be observed in the Scurfy mouse and in the corresponding human IPEX syndrome, leading to a Foxp3 localization restricted to the cytoplasm [27] . Similar mutations were observed in human breast carcinoma [13] and, as well as other transcriptional or posttranscriptional modifications, could induce its cytoplasmic rather than nuclear localisation in cancer cells. However, the exact biological function of cytoplasmic Foxp3 is presently undetermined, but our data suggest that, even in this cellular localization, Foxp3 seems to influence HER2 overexpressing breast cancer natural history. As we adhere to the REMARK criteria for tumor marker studies [28] , we analyzed our data according to systemic therapy groups. Interestingly, in subgroup analysis, the role of Foxp3 was found significant in the anthracycline group and with a trend toward significance in the trastuzumab group in univariate Cox proportional analysis. The absence of significance was probably due to the few rate of event in this group. Importantly, the multivariate analysis and the interaction testing found that the effect of Foxp3 cell on RFS is independent of the treatment. In sum, these data suggest that the prognostic relevance of tumor cell Foxp3 expression in HER2-overexpressing breast carcinoma is probably not influenced by modulation of the HER2 pathway induced by trastuzumab. However, we think that additional studies have to be performed to validate this result. Some articles demonstrated that Treg infiltrates in tumor bed may have a poor prognostic significance in early breast cancer [21, 29] , but in the both series, this prognostic role of Foxp3 Treg was not tested in HER2 overexpressing tumors. In this series of HER2 overexpressing breast carcinoma, Foxp3 expression in cancer cells is relevant for patient's prognostic while the presence of Foxp3? Treg in tumor bed have no prognostic behavior. In addition, these two informations are not stastistically correlated. These data strongly enforce our results, and suggest that Foxp3 expression is a really new and independent prognostic factor in HER2 overexpressing early breast cancer.
In conclusion, Foxp3 expression and function can no longer be considered to be restricted to the T-cell lineage, but may instead play a wider role in breast cancer cell biology. Our results suggest that Foxp3 expression in Treg and in tumor cells could have opposite prognostic values, at least in certain breast cancer varieties. This is a strong argument against using biomolecular methods such as mRNA expression by real-time polymerase chain reaction instead of immunohistochemistry for determining tumor infiltration by Foxp3? regulatory T cells. However, determination of Foxp3 expression consequences both in Treg and cancer cells will require further elucidation, especially in the context of new therapeutic strategies targeting Treg cells, and particularly Foxp3 expression [30] .
Taken together, our data suggest that Foxp3 expression in breast cancer cells could be a prognostic marker for patient outcome. However, our results also indicate that the influence of Foxp3 was dependent on the molecular subtype of breast cancer. Indeed, Foxp3 expression in cancer cells may be a marker of good prognosis in HER2-overexpressing tumors and of poor prognosis in other molecular subtypes of breast cancer. The issue of whether Foxp3 might become a clinically usable prognostic marker in breast carcinoma will need to be evaluated in other larger series of patients, and analysis will have to be stratified on breast molecular subtype, notably on HER2-overexpressing subtype.
